WELCOME TO
ExpreS2ion Biotech
INVESTOR SITE
Financial Calendar
- 16/05/23
Interim report, Q1 2023
- 24/05/23
Annual General Meeting, 2023
- 17/08/23
Half-year report, Q2 2023
- 16/11/23
Interim report, Q3 2023
- 08/02/24
Year-end report, 2023
Latest press releases
ExpreS2ion provides update on ABNCoV2 Phase III clinical trial
Regulatory pressreleaseHørsholm, Denmark, February 15, 2023– ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine. Today Bavarian Nordic announced that the top-line results are now anticipated around mid-2023 due to longer than expected recruitment…
Read moreExpreS2ion will present fourth quarter and full-year 2022 results
Non-regulatory pressreleaseHørsholm, Denmark, February 13, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") is pleased to announce that it will present fourth quarter and full-year 2022 results via webcast on February 15th, 2023, at 14:30 CET.
Read more